Benchmark Company Reiterates Buy Rating, $87 PT on Analogic Corporation on Ultrasonix Acquisition
In a report published Friday, Benchmark Company reiterated its Buy rating and $87.00 price target on Analogic Corporation (NASDAQ: ALOG).
Benchmark Company noted, “ALOG announced that the company completed the Ultrasonix Medical acquisition. Ultrasonix Medical is a supplier of advanced ultrasound systems for the point-of-care and general imaging markets with over 5,000 systems installed worldwide. We believe that this acquisition brings multiple benefits including an expanded product line, additional customers for cross-selling opportunities and an expanded sales channel including the sales and marketing infrastructure.”
Analogic Corporation closed on Thursday at $74.00.
Latest Ratings for ALOG
|Mar 2016||Sidoti & Co.||Initiates Coverage on||Neutral|
|Mar 2016||Brean Capital||Maintains||Buy|
|Mar 2015||Brean Capital||Upgrades||Hold||Buy|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.